A Phase I First-In-Human Multicenter Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumor
  • Age: Between 18 - 85 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Have previously proven microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status (confirmatory testing is not required). 2) Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status. 3) Have resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). 4) Must agree to have a first biopsy at baseline from a lesion that can be biopsied with an acceptable clinical risk (as judged by the Investigator in discussion with the interventional radiologist or endoscopist).

You may not be eligible for this study if the following are true:

  • 1) Has history of active or suspected autoimmune disease. 2) Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 3) Is expected to require any form of systemic or localized antineoplastic therapy while on study other than the study drugs. 4) Is receiving growth factors including, but not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, etc. within 4 weeks of study drugs administration.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.